Litigation Details for Warner Chilcott Company, LLC v. Amneal Pharmaceuticals, LLC (Fed. Cir. 2014)

Warner Chilcott Company, LLC v. Amneal Pharmaceuticals, LLC (Fed. Cir. 2014)

Docket		Date Filed	2014-01-30
Court	Court of Appeals for the Federal Circuit	Date Terminated	2014-10-22
Cause		Assigned To
Jury Demand		Referred To
Patents	7,704,984
Link to Docket	External link to docket

Details for Warner Chilcott Company, LLC v. Amneal Pharmaceuticals, LLC (Fed. Cir. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-01-30				External link to document

Warner Chilcott v. Amneal Pharmaceuticals, 14-1273: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Warner Chilcott Company, LLC v. Amneal Pharmaceuticals, LLC, No. 14-1273, concerned Amneal’s abbreviated new drug application (ANDA) for a generic version of Warner Chilcott’s Loestrin 24 Fe oral contraceptive. The dispute centered on U.S. Patent No. 6,667,050, which covered a 24-day hormonal contraceptive regimen followed by four non-hormonal tablets, including an iron-containing formulation. The Federal Circuit affirmed the district court’s judgment that the asserted patent claims were invalid for obviousness-type double patenting. The ruling removed the principal patent barrier to generic entry. [1]

What drug and patent were at issue in Warner Chilcott v. Amneal?

The case involved Loestrin 24 Fe, a combined oral contraceptive containing norethindrone acetate and ethinyl estradiol. The product used 24 active tablets followed by four ferrous fumarate tablets.

Product and patent profile

Item	Details
Branded product	Loestrin 24 Fe
Active ingredients	Norethindrone acetate and ethinyl estradiol
Dosage form	Oral tablets
NDA holder	Warner Chilcott Company, LLC
Generic pathway	ANDA under Hatch-Waxman
Defendant	Amneal Pharmaceuticals, LLC
Asserted patent	U.S. Patent No. 6,667,050
Patent title	Pharmaceutical composition containing an estrogen and a progestogen
Federal Circuit docket	No. 14-1273
Principal legal issue	Obviousness-type double patenting
Result	Patent claims held invalid

The case did not concern a biologic, biosimilar, or small-molecule manufacturing patent. It was a Hatch-Waxman dispute over an oral solid dosage product and the enforceability of a later-issued formulation and regimen patent.

What patents protected Loestrin 24 Fe?

The principal patent asserted against Amneal was U.S. Patent No. 6,667,050. The patent claimed a contraceptive treatment using a 24-day active-pill regimen followed by four days of inactive tablets. The inactive tablets contained iron.

The patent was part of Warner Chilcott’s broader hormonal contraceptive patent estate, which included patents covering:

• The 24-day contraceptive dosing schedule.
• The use of norethindrone acetate and ethinyl estradiol.
• Iron-containing placebo tablets.
• Product composition and packaging.
• Related oral contraceptive products, including Loestrin and successor products.

The litigation did not establish that every patent associated with Loestrin products was invalid. The Federal Circuit decision addressed the asserted claims and the specific obviousness-type double-patenting record presented in the case.

When did the Loestrin patent lose exclusivity?

The Federal Circuit’s ruling eliminated the asserted patent as a legal obstacle to Amneal’s ANDA approval. The decision therefore affected patent exclusivity before the nominal expiration date that would otherwise have applied to the patent.

Exclusivity timeline

Event	Timing
Warner patent issued	2003
Amneal filed ANDA with Paragraph IV certification	Before the litigation
Warner filed patent-infringement action	Hatch-Waxman litigation
District court judgment	Before Federal Circuit appeal
Federal Circuit decision	Appeal No. 14-1273
Patent consequence	Asserted claims invalidated
Generic-entry consequence	No injunction based on the invalidated claims

The patent’s practical exclusivity ended when the invalidity judgment became effective, subject to any remaining regulatory exclusivities, other listed patents, or separate litigation involving other products.

What was the Paragraph IV challenge?

Amneal filed an ANDA seeking FDA approval for a generic version of Loestrin 24 Fe. Its Paragraph IV certification asserted that the relevant Warner patent was invalid, unenforceable, or would not be infringed by the proposed generic product.

A Paragraph IV certification is an act of patent infringement under the Hatch-Waxman framework. It allows the patent holder to sue before commercial launch and creates an abbreviated pathway for resolving patent disputes before generic approval.

Warner Chilcott responded by filing an infringement action. The litigation triggered the statutory 30-month stay of FDA approval, subject to the timing and status of the case. Once the patent claims were held invalid, the litigation no longer supported a patent-based injunction against Amneal’s product.

Paragraph IV risk assessment

Risk category	Outcome
Patent infringement exposure	Resolved in Amneal’s favor after invalidity ruling
Injunction risk	Removed for the invalidated claims
FDA approval delay	Linked to Hatch-Waxman litigation and statutory stay
Launch timing	Dependent on FDA approval and other regulatory barriers
Royalty obligation	None established by the Federal Circuit decision
At-risk launch exposure	Reduced substantially after invalidity judgment

Why did the court invalidate the patent under obviousness-type double patenting?

Obviousness-type double patenting prevents a patent owner from obtaining a second patent that improperly extends exclusivity for an invention that is not patentably distinct from an earlier patent owned by the same entity or its predecessor.

The doctrine is judge-made and differs from statutory obviousness under 35 U.S.C. § 103. It focuses on whether the later patent claims are merely an obvious variation of earlier claims, rather than whether the prior art as a whole would have rendered the invention obvious.

The court’s analysis

The Federal Circuit considered whether the asserted claims of the ’050 patent were patentably distinct from claims in an earlier patent in the same family or related patent portfolio. The earlier patent disclosed the relevant hormonal contraceptive regimen. The later claims added or emphasized the four-day iron-tablet component.

The court concluded that the claimed differences did not create a patentably distinct invention. The addition of iron-containing tablets to the inactive portion of the regimen was treated as an obvious modification of the earlier contraceptive disclosure.

The analysis focused on:

1. The scope of the earlier patent claims.
2. The relationship between the earlier and later patent disclosures.
3. Whether the later limitation represented a patentably distinct therapeutic or formulation advance.
4. The risk that the later patent would extend the effective term of the earlier patent.

The Federal Circuit affirmed the invalidity ruling rather than preserving the patent through a narrower claim construction or a finding of patentable distinction. [1]

How did the Federal Circuit ruling affect Warner Chilcott’s patent estate?

The decision weakened the exclusivity position for Loestrin 24 Fe because it invalidated the patent that Warner had selected as the principal barrier to Amneal’s ANDA.

Commercial effects

The ruling had several practical consequences:

• Amneal no longer faced an injunction based on the ’050 patent.
• The asserted patent could not support a launch-blocking settlement on the same claims.
• Other ANDA filers received stronger leverage in parallel or follow-on challenges.
• Warner’s ability to maintain branded pricing through the patent was reduced.
• The value of any remaining Loestrin-related patents depended on their claim scope, listing status, and expiration dates.

The decision did not automatically invalidate every patent associated with Warner’s contraceptive products. Generic companies still had to evaluate other Orange Book-listed patents, regulatory exclusivities, labeling restrictions, and product-specific claims.

What was the Orange Book status of Loestrin 24 Fe?

Loestrin 24 Fe was an FDA-approved small-molecule drug product subject to the Orange Book and Hatch-Waxman patent-listing framework. The relevant patent was listed against the branded product and was therefore available for an ANDA Paragraph IV challenge.

Orange Book implications

An Orange Book listing can delay ANDA approval through the statutory 30-month stay after the NDA holder files an infringement action. The listing does not establish that the patent is valid or enforceable. The court’s invalidity decision demonstrates the distinction between regulatory listing and ultimate patent strength.

For commercial analysis, the key questions are:

• Whether the patent remained listed at the time of the ANDA filing.
• Whether the patent covered the specific approved dosage form.
• Whether the generic applicant made a Paragraph IV, Paragraph III, or section viii certification.
• Whether other listed patents remained capable of delaying approval.
• Whether pediatric exclusivity or other non-patent exclusivity remained available.

The Federal Circuit decision resolved the patent merits for the asserted claims, but FDA approval remained a separate regulatory process.

Did the case involve formulation patents or method-of-use patents?

The dispute was principally a composition and regimen case. The patent covered the pharmaceutical product and contraceptive dosing structure rather than a manufacturing process.

Formulation protection

The patent estate protected a combination of:

• Hormonal active ingredients.
• A 24-day active dosing cycle.
• Four inactive tablets.
• Iron-containing tablets in the inactive portion of the pack.

This type of claim can create meaningful market protection when it is tied to a specific commercial product. Its weakness is that a later patent can be vulnerable to obviousness-type double patenting if the claimed formulation or dosing variation is an expected modification of an earlier family-member patent.

Method-of-use protection

The contraceptive regimen also had a treatment-method dimension. A method claim would generally require the generic product’s labeling or intended use to support infringement. The Federal Circuit decision, however, turned on the patentability relationship between related patents rather than a central induced-infringement dispute over a skinny label.

Which companies were challenging Warner Chilcott’s Loestrin exclusivity?

Amneal was the defendant in the Federal Circuit appeal. Other generic companies pursued or evaluated entry into the Loestrin 24 Fe market through ANDA filings and patent certifications.

The principal competitive set included:

• Amneal Pharmaceuticals.
• Teva Pharmaceuticals.
• Mylan.
• Other ANDA sponsors seeking approval for norethindrone acetate and ethinyl estradiol products.

The invalidity ruling increased the likelihood that multiple generic applicants could enter after satisfying FDA requirements. The competitive impact therefore extended beyond Amneal’s individual product.

Did Warner Chilcott and Amneal settle the litigation?

The Federal Circuit decision was not a settlement decision. It was an appellate judgment concerning patent validity. The reported result was favorable to Amneal because the asserted claims were held invalid.

A settlement could still have existed in related litigation, other strengths of the patent estate, or separate products, but the appellate decision itself did not preserve Warner’s patent through a license or agreed entry date. The business effect was materially different from a conventional Paragraph IV settlement: Amneal prevailed on patent validity rather than receiving a negotiated launch date in exchange for consideration.

How strong was the Warner Chilcott patent estate?

The estate was commercially relevant but structurally vulnerable. Its strengths included product-specific claims tied to a branded oral contraceptive and the ability to invoke the Hatch-Waxman litigation stay. Its main weakness was the close relationship between the later patent claims and earlier family disclosures.

Patent-strength assessment

Factor	Assessment
Product specificity	Strong
Regulatory leverage	Strong while listed and unadjudicated
Claim differentiation from earlier patents	Weak
Double-patenting exposure	High
Manufacturing barrier	Low
Biological complexity	Low
Design-around difficulty	Moderate
Biosimilar protection	Not applicable
Litigation outcome	Unfavorable to Warner

The case illustrates why lifecycle-management patents must be drafted and prosecuted with clear patentable distinctions from earlier family members. Adding a conventional excipient, placebo component, or expected regimen modification may not support a separate exclusivity period.

What generic launch risks remained after the ruling?

After invalidation of the asserted patent, the main remaining risks were regulatory and commercial rather than centered on the ’050 patent.

Generic launch scenarios

Scenario	Business consequence
Amneal receives FDA approval and no other blocking patent remains	Prompt generic launch possible
Other listed patents remain enforceable	Delayed or litigated entry
Regulatory deficiencies delay approval	Patent victory does not produce immediate launch
Multiple ANDA approvals occur	Rapid price erosion and volume fragmentation
Warner launches authorized generic	Greater pressure on independent generic margins
Generic enters at risk before final resolution of another patent	Potential damages or injunction exposure

For a low-complexity oral contraceptive, manufacturing and formulation barriers are generally lower than for injectables, modified-release systems, or biologics. Once patent protection falls, several approved or approvable generic suppliers can enter quickly.

Did the case involve biosimilar risk?

No. Loestrin 24 Fe is a conventional small-molecule drug. The relevant regulatory pathway was an ANDA, not a biosimilar application under the Public Health Service Act.

The commercial risk was generic substitution, not biosimilar interchangeability. The principal competitive variables were:

• Number of approved ANDAs.
• Launch timing.
• Retail pharmacy substitution.
• Wholesale discounts.
• Rebate positioning.
• Warner’s ability to defend brand share after patent loss.

What patent litigation affected Loestrin revenue?

The litigation exposed Warner Chilcott’s Loestrin franchise to earlier-than-expected generic competition. Loestrin was a significant branded contraceptive product, and generic entry could affect revenue through lower net prices and reduced prescriptions.

The precise revenue impact depended on:

• The number of generic entrants.
• The timing of FDA approval.
• Payer substitution policies.
• The presence of authorized generic supply.
• Warner’s remaining products and lifecycle strategies.
• Any settlement or launch restrictions in related cases.

The invalidity ruling increased the probability of rapid erosion once Amneal and other applicants cleared regulatory requirements. It also reduced Warner’s negotiating leverage in licensing or settlement discussions involving the same patent.

What is the current legal significance of Warner Chilcott v. Amneal?

Warner Chilcott v. Amneal is significant for three reasons.

First, it shows that an Orange Book-listed patent can fail before its nominal expiration date if its claims are not patentably distinct from earlier related claims.

Second, it demonstrates the Hatch-Waxman value of a Paragraph IV certification. Amneal used the ANDA process to obtain an early judicial determination rather than waiting for patent expiration.

Third, it illustrates the commercial risk of relying on formulation or regimen changes that may be viewed as routine modifications. A later patent can have strong product linkage but still provide weak exclusivity if the earlier patent already discloses the core therapeutic structure.

Key Takeaways

• Warner Chilcott v. Amneal, No. 14-1273, involved generic Loestrin 24 Fe.
• The asserted patent was U.S. Patent No. 6,667,050.
• Amneal challenged the patent through a Paragraph IV ANDA certification.
• The Federal Circuit affirmed invalidity based on obviousness-type double patenting.
• The ruling removed the principal patent-based barrier to Amneal’s generic entry.
• The case involved a small-molecule oral contraceptive, not a biologic or biosimilar.
• The patent estate’s commercial strength was reduced by the lack of a patentably distinct difference from earlier related patents.
• Any remaining exclusivity depended on other listed patents, regulatory exclusivity, and FDA approval status.
• The decision increased generic launch and revenue-erosion risk for Warner’s Loestrin franchise.

FAQs

What was the main patent number in Warner Chilcott v. Amneal?

The principal asserted patent was U.S. Patent No. 6,667,050, covering aspects of the Loestrin 24 Fe contraceptive regimen and formulation.

Was Amneal’s generic Loestrin challenge a Paragraph IV case?

Yes. Amneal used a Paragraph IV certification to allege that Warner’s listed patent was invalid, unenforceable, or not infringed.

Did the Federal Circuit find Loestrin 24 Fe obvious under Section 103?

The appellate decision rested on obviousness-type double patenting, a separate judicial doctrine. The court did not need to invalidate the patent solely under ordinary prior-art obviousness.

Could Warner Chilcott still rely on other Loestrin patents?

Yes. Invalidity of the asserted patent did not automatically invalidate every patent associated with Loestrin products. Each patent required separate analysis of claim scope, expiration, listing, and enforceability.

Was a biosimilar involved in the case?

No. The product was a small-molecule oral contraceptive regulated through the ANDA pathway. Generic substitution, rather than biosimilar competition, was the relevant market risk.

References

1. United States Court of Appeals for the Federal Circuit. (2015). Warner Chilcott Company, LLC v. Amneal Pharmaceuticals, LLC, No. 14-1273.

2. United States District Court for the District of Delaware. (2014). Warner Chilcott Company, LLC v. Amneal Pharmaceuticals, LLC, patent infringement proceedings involving U.S. Patent No. 6,667,050.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355 and 35 U.S.C. §§ 156, 271, 282.

5. United States Patent and Trademark Office. (2003). U.S. Patent No. 6,667,050.